Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8124245 | 0.84 | ALDH1A1 (0.52) | CA1CA2CA9ALDH1A1GAA | |
| SCHEMBL3960782 | 0.84 | GAA (0.50) | CA1CA2CA9ALDH1A1GAA | |
| SCHEMBL30589526 | 0.78 | ALDH1A1 (0.46) | ALDH1A1CYP3A4L3MBTL1TDP1ALDH1A3 | |
| SCHEMBL3937172 | 0.78 | ALDH1A1 (0.46) | ALDH1A1CYP3A4L3MBTL1TDP1ALDH1A3 | |
| SCHEMBL10330733 | 0.77 | ALDH1A1 (0.45) | CA1CA2CA9ALDH1A1CYP3A4 | |
| SCHEMBL20607030 | 0.75 | ERN1 (0.55) | ALDH1A1CYP3A4TDP1ERN1 | |
| SCHEMBL8950525 | 0.75 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1TDP1ALDH1A3ERN1 | |
| SCHEMBL13144650 | 0.75 | ALDH1A1 (0.41) | ALDH1A1TDP1ALDH1A3MAPK1ERN1 | |
| SCHEMBL3309062 | 0.72 | KIF11 (0.39) | CA1CA2CA9ALDH1A1GAA | |
| SCHEMBL1205444 | 0.71 | ALDH1A1 (0.39) | ALDH1A1GAACYP3A4L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7696209-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20090186881-A1 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-7528129-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| CN-101146799-A | Cgrp-antagonists, process for their preparation as well as their use as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2008-03-19 | — | — | CN | disclosed |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186881-A1 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CA1 2066/4885CA2 1028/4885CA9 2611/4885 |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CA1 1729/4885CA2 972/4885CA9 2720/4885 |
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CA1 1729/4885CA2 972/4885CA9 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.